Todd Krueger

Todd Krueger has had a long and varied career in business. Todd began their career in 1994 as a Summer Associate at McKinsey & Company. In 1999, they became the CFO and Co-Founder of Fluidigm Corporation. In 2002, they joined RTK Group as a Partner. In 2006, they became the Head of Business Development Molecular Medicine and Companion Diagnostics at Life Technologies. In 2010, they joined Achieve Mission as a Board of Director. In 2014, they became the Head of Commercial Strategy and Operations at the Broad Institute, as well as the Chairman and Co-Founder of Isolation Bio. In 2015, they joined AOBiome Therapeutics as President and CEO, and also joined Neofluidics as a Board of Director. In 2020, they joined Tenza as a Board of Director. In 2021, Neofluidics was sold to Private Equity.

Todd Krueger's education history includes a Bachelor of Arts degree in Economics from Northwestern University, which they obtained between 1987 and 1990. Todd then attended Northwestern University's Kellogg School of Management, where they earned an MBA in Finance and Strategic Decision Making between 1993 and 1995. Additionally, Todd attended grammar school and University High School, though the years they attended are unknown.